2nd Annual Molecular Glue Drug Development Summit

Event Details:

January 30th - February 1st | Boston, MA

Applied BioMath Presence:

Presentation Title: Guiding Target Selection and Lead Optimization for a Molecular Glue Degrader


Applying model-informed drug discovery and development (MID3) early in development can reduce late-stage risk by determining feasibility of drugging a given target, prioritizing between targets, or defining optimal drug properties for a target product profile. However, the lack of pharmacokinetic (PK) and pharmacodynamic (PD) data available at early stages can make modeling a challenge. We have developed Early Feasibility Assessment (EFA), a method for making development decisions based on mechanistic models built from general biophysical principles and parameterized by data that is readily available early in drug discovery. The presentation will demonstrate how to use Applied BioMath's MGD AssessTM model to:

  • Optimize drug properties by exploring MGD binding parameters for a specific ligase-target pair to maximize its potency
  • Inform target selection by evaluating the dependence of target expression and turnover on its degradation profile

Presenter: Josh Apgar, PhD, Co-Founder and CSO of Applied BioMath

Day and Time: Thursday, February 1st | 10:00am